Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder among women of reproductive age, estimated to affect approximately 10% of this population globally. Its pathophysiology is multifactorial, involving insulin resistance, hyperandrogenism, ovulatory dysfunction, and low-grade chronic inflammation. Standard pharmacological approaches have historically targeted individual features of the syndrome in isolation. Emerging preclinical and clinical research has begun to examine whether peptide-based compounds — particularly incretin mimetics and tissue-repair peptides — may interact with the overlapping metabolic and endocrine pathways characteristic of PCOS. This article summarises current findings in the published literature on peptides for PCOS.

The Metabolic Basis of PCOS and the Role of Incretin Peptides

A substantial body of research has established that insulin resistance plays a central mechanistic role in PCOS, contributing to compensatory hyperinsulinaemia that in turn stimulates excess androgen production in ovarian theca cells. Researchers have proposed that compounds capable of modulating insulin sensitivity and glucose homeostasis may therefore exert downstream effects on the hormonal environment of PCOS.

Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its principal physiological role involves stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. GLP-1 receptors have been identified not only in pancreatic tissue but also in the hypothalamus, pituitary, and ovary — an anatomical distribution that has prompted research interest in GLP-1 receptor agonists (GLP-1 RAs) in the context of reproductive endocrinology.

GLP-1 Receptor Agonists: Observed Metabolic Effects in PCOS Models

Multiple randomised controlled trials and meta-analyses have examined GLP-1 receptor agonist compounds — including liraglutide, exenatide, and semaglutide — in female subjects with PCOS. A 2025 meta-analysis published in Scientific Reports evaluated GLP-1 RAs against metformin and placebo across multiple outcomes including body mass index, waist-to-hip ratio, fasting insulin, HOMA-IR, and sex hormone-binding globulin (SHBG). Researchers observed that GLP-1 RA treatment was associated with statistically significant changes in markers of insulin resistance and androgen exposure relative to comparators.

A 2025 narrative review in Endocrine Connections further reported that low-dose semaglutide treatment in women with PCOS who were unresponsive to lifestyle interventions was associated, in observational data, with changes in basal glucose, insulin resistance as measured by HOMA-IR, and menstrual cycle regularity. The authors noted that such observations require confirmation in larger controlled trials before mechanistic conclusions can be drawn.

Retatrutide and Multi-Receptor Agonism: Emerging Research in Peptides for PCOS

The evolution of incretin-based research has moved beyond single-receptor GLP-1 agonism toward dual and triple receptor co-agonist compounds. Retatrutide (LY3437943), a triple agonist of the GLP-1, GIP, and glucagon receptors (GCGR), has attracted substantial research interest for its capacity to simultaneously engage three complementary metabolic pathways — enhancing insulin secretion, reducing appetite, and increasing energy expenditure via glucagon receptor-mediated thermogenesis.

A 2025 scoping review published in Cureus specifically examined the research landscape of incretin mimetics — including semaglutide, tirzepatide, and retatrutide — in the context of PCOS pathophysiology. Researchers noted that the addition of GIP receptor agonism in dual and triple-acting compounds appeared, in reviewed data, to produce greater reductions in markers associated with hyperinsulinaemia relative to GLP-1 monotherapy. The review highlighted that the glucagon receptor component of retatrutide introduces an energy expenditure pathway not present in earlier GLP-1 RA compounds, which researchers proposed could be mechanistically relevant to the adipose tissue burden and metabolic dysfunction observed in obese PCOS phenotypes.

It is important to note that as of 2025–2026, retatrutide remains an investigational compound in active Phase 3 clinical trials. No regulatory approval for any indication has been granted at time of writing, and no published data have examined retatrutide specifically in PCOS subject populations. The proposed mechanistic relevance to PCOS represents an extrapolation from established pharmacology and general metabolic trial data, not direct clinical evidence in this population.

GHK-Cu and Ovarian Tissue: Oxidative Stress and Cellular Signalling Research

Beyond the incretin class, preclinical research has examined whether copper-binding peptides — specifically the tripeptide glycine-histidine-lysine complexed with copper (GHK-Cu) — may interact with inflammatory and oxidative pathways relevant to PCOS. The ovarian microenvironment in PCOS is characterised by elevated oxidative stress markers and pro-inflammatory cytokine activity in granulosa cells, factors that have been associated with impaired follicular development and oocyte quality in multiple published studies.

GHK-Cu has been extensively investigated in vitro for its capacity to modulate transcriptional activity, reduce pro-inflammatory cytokine expression, and influence extracellular matrix remodelling. Research observations include altered signalling associated with tumour necrosis factor-related pathways and interleukin-mediated responses in fibroblast and immune-associated cell models.

Separately, published research on the ovarian granulosa cell environment in PCOS has confirmed that elevated inflammatory markers — including TNF-α, IL-6, and HIF-1α — and heightened oxidative stress are characteristic features of granulosa cells isolated from PCOS subjects relative to healthy controls. This establishes a mechanistic rationale for investigating compounds with demonstrated anti-inflammatory and antioxidant properties in this cellular context, though direct studies on GHK-Cu in PCOS subject-derived tissue remain limited.

Researchers have noted that GHK-Cu's influence on gene expression profiles related to cell growth, oxidative stress, and inflammation provides a mechanistic framework for further investigation, while emphasising that the majority of current evidence remains preclinical, with human-centred trial data sparse.

Research Limitations and Outstanding Questions

The existing literature on peptides for PCOS reflects a rapidly developing but still early-stage evidence base. Several limitations warrant careful consideration when reviewing current findings:

Heterogeneity of PCOS phenotypes. PCOS encompasses at least four recognised Rotterdam criteria-defined phenotypes with meaningfully different hormonal and metabolic profiles. Published trials have not consistently stratified findings by phenotype, limiting the generalisability of observed results.

Short follow-up periods. Most published trials on GLP-1 RAs in PCOS have follow-up periods of 16–48 weeks. The long-term trajectory of observed metabolic and endocrine changes — particularly whether they persist following compound cessation — remains incompletely characterised in the peer-reviewed literature.

Absence of direct mechanistic data for newer compounds. Retatrutide has not been studied directly in PCOS subject populations in any published peer-reviewed trial to date. Mechanistic proposals are based on receptor pharmacology and metabolic data from general obesity trial populations.

Preclinical-to-clinical translation gap for GHK-Cu. The relevant in vitro and animal model data on GHK-Cu in reproductive tissue contexts has not yet been replicated in controlled human trials. Researchers note this as a primary gap requiring prospective study.

Summary

Published preclinical and clinical research has identified several peptide-class compounds with mechanistic profiles relevant to the overlapping metabolic, inflammatory, and endocrine features of PCOS. GLP-1 receptor agonists have the strongest clinical evidence base in this context, with multiple randomised trials and meta-analyses documenting observed changes in insulin resistance markers, androgen indices, and metabolic parameters in PCOS subject populations. Multi-receptor agonist compounds such as retatrutide introduce additional pharmacological pathways — GIP and glucagon receptor co-agonism — that research suggests may produce additive metabolic effects, though direct PCOS-specific trial data are not yet available. GHK-Cu represents an earlier-stage area of research interest, with in vitro data indicating relevant activity in oxidative stress and inflammatory signalling pathways within the ovarian granulosa cell environment. All findings reviewed here derive from laboratory and clinical research settings and are presented for scientific reference only.